Adds extensive life science senior experience and transactional capability to the Board of Directors
Fort Collins, CO, July 1, 2020 – Cetya Therapeutics, Inc. announces the appointment of Mr. Ron A. Lowy to its Board of Directors. Mr. Lowy fills a vacant position due to the passing of Founding Scientist Robert Williams, PhD, in May. Dr. Williams was University Distinguished Professor of Chemistry at Colorado State University, and a world-renowned expert in the chemistry of natural and synthetic heterocyclic compounds.
Mr. Lowy serves on the boards and as an advisor to multiple medical device, education and information technology companies. He is currently the Executive Chairman of PharmaJet, Inc, a needle-free injection technology company, Chairman of FluoroFinder, a developer and provider of cloud-based medical research tools and Chairman of the Advisory Board of Phase Holographic imaging, a provider of non- invasive cell imaging technology. He previously served as the President and CEO of the Biosciences division of Thermo Fisher Scientific, Inc. He spent the first 15 years of his career in operations, technology and general management positions at GE Healthcare where he was active in GE’s development of Computerized Tomography (CT), Magnetic Resonance (MR) and multiple imaging technologies. Mr. Lowy holds a Bachelor of Science degree in Mechanical Engineering from the University of New Hampshire and an MBA from the University of Wisconsin.
“We are fortunate to have someone of Ron Lowy’s caliber and experience fill the vacant seat on our Board,” said Cliff Hendrick, CEO of Cetya. “We are at a critical moment and Mr. Lowy will bring new insights and vision to assist in successfully implementing our strategy to optimize the encouraging data flow from our Sickle Cell disease program. Mr. Lowy has a proven track record of leadership and execution. He is a strong communicator who is customer focused and with deep leadership capabilities.”
“I am thrilled to join the Board of Cetya as it pursues its novel drug therapy for Sickle Cell Disease, a disorder of the underserved African-American community” stated Mr. Lowy. “The sickle cell data looks very promising, and the company appears to be at an inflection point in its history and valuation. I am looking forward to helping Cetya continue to grow and achieve its goals in hemoglobin disorders and in oncology.
About Cetya Theraeutics
Cetya Therapeutics, Inc. is a development stage pharmaceutical company developing histone deacetylase inhibitors structurally based on the marine natural product Largazole. Cetya has the exclusive worldwide rights to the histone deacetylase (HDAC) inhibitor platform and patent estate developed in the laboratory of Dr. Robert M. Williams at CSU. Cetya has a portfolio of analogs, including CT-102, to evaluate in solid tumor indications and has selected a lead candidate for treatment of hemoglobin disorders such as Sickle Cell Disease. Cetya is seeking corporate partners to assist in the advancement of its analog portfolio in a number of different therapeutic indications. For more information on Cetya, please visit our website at www.cetyatherapeutics.com or contact Cliff Hendrick at firstname.lastname@example.org